Search
Aeon Biopharma Inc
AEONAdd to Watchlist
0.298USD
+0.043+16.81%
Close 07-31 16:00（ET）Quotes delayed by 15 min
7.54MMarket Cap
LossP/E TTM
More Details of Aeon Biopharma Inc Company
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.
Aeon Biopharma Inc Info
Ticker SymbolAEON
Company nameAeon Biopharma Inc
IPO dateFeb 09, 2021
CEOBancroft (Robert E)
Number of employees5
Security typeOrdinary Share
Fiscal year-endFeb 09
Address5 Park Plaza
CityIRVINE
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code92614
Phone19493546499
Websitehttps://aeonbiopharma.com/
Ticker SymbolAEON
IPO dateFeb 09, 2021
CEOBancroft (Robert E)
Company Executives of Aeon Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jost Fischer
Mr. Jost Fischer
Independent Chairman of the Board
Independent Chairman of the Board
495.97K
+44.90%
Mr. Robert J. (Bob) Palmisano
Mr. Robert J. (Bob) Palmisano
Independent Director
Independent Director
254.14K
+87.62%
Mr. Marc Forth
Mr. Marc Forth
Director
Director
222.68K
--
Dr. Chad Oh, M.D.
Dr. Chad Oh, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Alex Wilson
Mr. Alex Wilson
Executive Vice President, Chief Legal Officer, Corporate Secretary
Executive Vice President, Chief Legal Officer, Corporate Secretary
--
--
Dr. Eric Carter, M.D., Ph.D.
Dr. Eric Carter, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Shelley Thune
Ms. Shelley Thune
Independent Director
Independent Director
--
--
Mr. Seongsoo Park
Mr. Seongsoo Park
Director
Director
--
--
Ms. Jennifer Sy
Ms. Jennifer Sy
Principal Financial Officer, Chief Accounting Officer
Principal Financial Officer, Chief Accounting Officer
--
-100.00%
Mr. Robert Bancroft
Mr. Robert Bancroft
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jost Fischer
Mr. Jost Fischer
Independent Chairman of the Board
Independent Chairman of the Board
495.97K
+44.90%
Mr. Robert J. (Bob) Palmisano
Mr. Robert J. (Bob) Palmisano
Independent Director
Independent Director
254.14K
+87.62%
Mr. Marc Forth
Mr. Marc Forth
Director
Director
222.68K
--
Dr. Chad Oh, M.D.
Dr. Chad Oh, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Alex Wilson
Mr. Alex Wilson
Executive Vice President, Chief Legal Officer, Corporate Secretary
Executive Vice President, Chief Legal Officer, Corporate Secretary
--
--
Dr. Eric Carter, M.D., Ph.D.
Dr. Eric Carter, M.D., Ph.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Aeon Biopharma Inc?
The top five shareholders of Aeon Biopharma Inc are: Mr. Jost Fischer
How many institutions hold shares of Aeon Biopharma Inc (AEON)?
As of 2026Q1, 69 institutions hold shares of Aeon Biopharma Inc, with a combined market value of approximately 2.00M, accounting for 7.61% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -100655.00.